TCM
GBT

TimesSquare Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

TimesSquare Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,263,710
Closed -$79.8M – 251
2020
Q2 		$79.8M Buy
1,263,710
+716,460
+131% +$49.1M 0.76% 36
2020
Q1 		$28M Buy
547,250
+389,350
+247% +$26.1M 0.33% 129
2019
Q4 		$12.6M Buy
+157,900
New +$9.36M 0.11% 191

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TimesSquare Capital Management's GBT Position: Q3 2020 in Review

TimesSquare Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2020, closing a stake of 1,263,710 shares — an estimated $79.8M sold.

TimesSquare Capital Management first reported a position in GBT in Q4 2019 and held it in 3 quarters. The position peaked at $79.8M in Q2 2020. 229 funds tracked by Wall St. Rank hold GBT as of Q3 2020.

  • TimesSquare Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • TimesSquare Capital Management sold 1,263,710 Global Blood Therapeutics, Inc. shares in Q3 2020, an estimated $79.8M.
  • TimesSquare Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 3 quarters.
  • TimesSquare Capital Management's Global Blood Therapeutics, Inc. position peaked at $79.8M in Q2 2020.
  • 229 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2020.

Based on TimesSquare Capital Management's 13F filing for Q3 2020, filed 6 Nov 2020.